Evonik Shares Hold Near 52-Week High as Labor, Politics and a Rebuffed BASF Bid Collide

Evonik stock trades just below its 52-week high as BASF's rejected EUR 10.3 billion approach keeps a takeover premium in the share price.

Evonik's stock is trading within a whisker of its annual peak, and the reason has little to do with the specialty chemicals maker's day-to-day business. A takeover approach from rival BASF has injected a speculative premium into the share price that now sits at the center of every investor's calculus.

The Essen-based company closed yesterday at EUR 21.06, roughly 0.9% shy of its 52-week high of EUR 21.26. Since news of Ludwigshafen-based BASF's interest surfaced about a week ago, the stock has climbed 3.8%, extending its year-to-date advance to 58%. For existing shareholders, the character of the holding has shifted: operational metrics have faded into the background while deal tactics take center stage.

A EUR 10.3 Billion Offer Rejected

At the heart of the standoff is valuation. According to a Reuters report, Evonik dismissed an initial approach worth EUR 10.3 billion as too low. That figure equates to EUR 22.15 per share, a premium of about 23% to the undisturbed price. Both companies have confirmed only informal exploratory talks, with no formal negotiations currently underway. BASF has described the outcome and timing of those soundings as open.

The decision now rests on whether a suitor is prepared to table a substantially richer bid. Analyst Sebastian Bray of Berenberg assigned a "Hold" rating on October 5 with a EUR 20 price target, citing the takeover interest directly. A day later, research firm Parmantier & Cie. also issued a hold recommendation, with a EUR 20.50 target. The market's message is clear: the known parameters of the offer are already baked into the current quote, and any further move requires a fresh financial signal from the other side or from major shareholders.

Labor Draws a Line in the Sand

Employee representatives have wasted no time making their position known. In a three-page letter to works councils at both companies, IGBCE chief Michael Vassiliadis and Alexander Bercht, Evonik's deputy supervisory board chairman, urged caution. There must be no rush to judgment on any potential transaction, they warned, according to reports from dpa and Handelsblatt.

Bigger is not automatically better, the labor leaders stressed. They are demanding a binding plan for standalone growth from management, arguing that past cost-cutting programs have mainly delivered job reductions. Future steps, they insist, must offer credible prospects for sites and employees. Vassiliadis carries particular weight in this debate: he sits on BASF's supervisory board as well as representing workers at Evonik. Without a comprehensive industrial concept, the IGBCE warns, a takeover would primarily pursue synergies through headcount cuts.

RAG Foundation and Political Headwinds

The RAG Foundation, Evonik's anchor shareholder with a 43% stake, holds another key card. The foundation channels dividend income to fund perpetual liabilities from German hard-coal mining. Vassiliadis also serves on the foundation's board of trustees, which convened a special meeting today. No preliminary decision on a sale was on that agenda.

Politicians are weighing in too. The SPD in North Rhine-Westphalia has floated the idea of the state taking a stake in Evonik, though no such resolution has been passed. For investors, these interventions underscore how tangled the environment around the specialty chemicals group has become. Management, meanwhile, is pressing ahead with a sweeping corporate restructuring aimed at strengthening earnings power on its own.

Two Paths, One Share Price

In an optimistic scenario, the bidder sweetens its offer to overcome resistance from management and owners. Should the parties move to formal talks, a premium above the rejected sum becomes conceivable, and an official cash offer above the previously reported level would drive the stock higher still. Additional momentum could build if institutional heavyweights such as the RAG Foundation signal a clear willingness to sell at a fixed price. Even absent a full takeover, the current spotlight could highlight the value of Evonik's portfolio, potentially easing strategic partnerships or partial divestments down the road.

The downside is equally pronounced. If the soundings collapse for good, the takeover premium would evaporate from the share price almost instantly, forcing the valuation back onto operating fundamentals alone. Complicating matters, media reports indicate the IGBCE is demanding clarity on sites and jobs while counseling restraint, and the SPD's state parliamentary group has called on the state government to block a takeover, raising the prospect of a public stake. Such debates can entangle negotiations or scare off interested parties. Investors who bought in at current levels would bear the full brunt of a disappointment-driven correction.

The Next Catalyst

So long as the prospect of an improved offer underpins trading, the stock is likely to hover near its recent highs. Should talks falter without a concrete result, a swift slide back toward analysts' average price targets looms. The next fundamental milestone arrives on November 3, when Evonik publishes its third-quarter interim report. Until those figures land, the shares remain at the mercy of headlines about a possible transaction.